In animal experiments, inhibition of ACC2 can increase hepatic fat oxidation, reduce hepatic lipids, and improve hepatic insulin sensitivity in mice with NAFLD (31), which is further confirmed in mice with genetic depletion of ACC2 (3, 32, 33). Here, ACACB is linked to metabolic dysfunction-associated steatotic liver disease.